Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
AVAILABLE
Study Classification
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Zofin (Organicell Flow) for Patients With COVID-19
NCT04384445
Corona Virus Infection
COVID-19
SARS
+1 more
COMPLETED
PHASE1/PHASE2
Zofin to Treat COVID-19 Long Haulers
NCT05228899
COVID-19
COMPLETED
PHASE1/PHASE2
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
NCT04632381
Corona Virus Infection
COMPLETED
PHASE1
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
NCT05195749
COVID-19
TERMINATED
PHASE2
A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19
NCT04460183
COVID-19
COMPLETED
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A human coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak worldwide. Common symptoms of COVID-19 include fever, cough, and shortness of breath. The majority of cases result in mild symptoms, but some can progress into pneumonia and multi-organ failure. According to the severity it is divided into mild, normal, severe and critically ill, which is associated with ICU admission and mortality. At present, the standard treatment of COVD-19 patients is oxygen therapy, mechanical ventilation, and medications to maintain blood pressure. As of today, no specific antiviral therapy is available for patients with COVID-19. Immune activation in some patients, and the appearance of cytokine storm syndrome (CSS) is one of the important causes of severe damage to lungs and other organs, which may lead to death. There is an urgent need to develop new interventions to suppress the excessive immune response in a timely manner during the course of disease, protect alveolar function, and reduce lung and systemic organ damage.
Zofin is an acellular, minimally manipulated product, derived from human amniotic fluid (HAF). This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and epithelial cells. The product contains a mean concentration of 5.24x10\^11 particles/mL with a mean mode size of 125.2nm. Surface marker analysis confirmed the presence of exosome associated proteins CD63, CD81, and CD9 in addition to high expression of CD133. The completed sequencing revealed 102 commonly expressed miRNA (with a 100-copy expression minimum). Bioinformatics analysis linked 63 miRNAs to 1216 RNA targets. Major players in the proinflammatory cytokine cascade found to be targeted by miRNA were discovered in Organicell's product include TNF, IL-6, and IL-8. Additionally, a broader array of pro-inflammatory cytokines is also targeted by the collection of miRNA such as FGF2, IFNB1, IGF1, IL36a, IL37, TGF-B2, VEGFA, CCL8, and CXCL12. It has been suggested in published research that inhibition or suppression of this pro-inflammatory cytokine cascade may reduce the severity of symptoms associated with elevated immune response. Furthermore, the miRNA was found to target 148 genes associated with immune response.
The property of Zofin demonstrates the therapeutic potential as a suppressor of cytokine activation for the reduction of COVID-19 infection severity. This is an open label expanded access protocol to treat subjects using ZofinTM (OrganicellTM Flow) for treatment of mild to moderate COVID-19 due to SARS-Cov-2.
Zofin is an acellular, minimally manipulated product, derived from human amniotic fluid (HAF). This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and epithelial cells. The product contains a mean concentration of 5.24x10\^11 particles/mL with a mean mode size of 125.2nm. Surface marker analysis confirmed the presence of exosome associated proteins CD63, CD81, and CD9 in addition to high expression of CD133. The completed sequencing revealed 102 commonly expressed miRNA (with a 100-copy expression minimum). Bioinformatics analysis linked 63 miRNAs to 1216 RNA targets. Major players in the proinflammatory cytokine cascade found to be targeted by miRNA were discovered in Organicell's product include TNF, IL-6, and IL-8. Additionally, a broader array of pro-inflammatory cytokines is also targeted by the collection of miRNA such as FGF2, IFNB1, IGF1, IL36a, IL37, TGF-B2, VEGFA, CCL8, and CXCL12. It has been suggested in published research that inhibition or suppression of this pro-inflammatory cytokine cascade may reduce the severity of symptoms associated with elevated immune response. Furthermore, the miRNA was found to target 148 genes associated with immune response.
The property of Zofin demonstrates the therapeutic potential as a suppressor of cytokine activation for the reduction of COVID-19 infection severity. This is an open label expanded access protocol to treat subjects using ZofinTM (OrganicellTM Flow) for treatment of mild to moderate COVID-19 due to SARS-Cov-2.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Covid19
Corona Virus Infection
SARS (Severe Acute Respiratory Syndrome)
Acute Respiratory Distress Syndrome
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zofin
Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10\^11 particles/mL.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Organicell Flow
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Provide written informed consent
2. Subjects age \> 18 years at the time of signing the Informed Consent Form.
3. Male or Female
4. Must have a clinical diagnosis of COVID-19 by the qualitative reverse-transcription polymerase chain reaction (RT-PCR), with at least one of mild or moderate COVID-19 clinical symptoms which are defined below in #5
5. Individuals with mild to moderately COVID-19 symptoms for outpatient and inpatient population.
The main symptoms of mild illness are:
* low grade fever \<38°C (37.5 to 37.9)
* a dry cough
* tiredness
* feeling slightly breathless
* muscle pain
* headache
* sore throat
* diarrhea
The main symptoms of moderate illness are:
In addition to the symptoms patients may get with a mild illness, they may also experience:
* fever ≥38°
* a dry and more persistent cough several times an hour
* tiredness and a need to stay in bed
* feeling breathless when doing moderate exercise (such as walking upstairs)
* muscle pain and aches and need to stay in bed
* headache particularly if you are feeling hot
* sore throat, soreness from coughing, but no pain
* diarrhea
* a dry mouth
6. Adequate venous access
7. For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment. The FDA-approved and cleared methods for birth control are listed below:
* Permanent Sterilization
* Long-Acting Reversible Contraceptives (LARC)
* Contraceptive Injection
* Short-Acting Hormonal Methods
* Barrier Methods
* Emergency Contraception
https://www.fda.gov/consumers/free-publications-women/birth-control
8. Any male subject must agree to use contraceptives and not donate sperm during the study.
9. Must agree to comply with all protocol requirements and be willing to complete all study visits
2. Subjects age \> 18 years at the time of signing the Informed Consent Form.
3. Male or Female
4. Must have a clinical diagnosis of COVID-19 by the qualitative reverse-transcription polymerase chain reaction (RT-PCR), with at least one of mild or moderate COVID-19 clinical symptoms which are defined below in #5
5. Individuals with mild to moderately COVID-19 symptoms for outpatient and inpatient population.
The main symptoms of mild illness are:
* low grade fever \<38°C (37.5 to 37.9)
* a dry cough
* tiredness
* feeling slightly breathless
* muscle pain
* headache
* sore throat
* diarrhea
The main symptoms of moderate illness are:
In addition to the symptoms patients may get with a mild illness, they may also experience:
* fever ≥38°
* a dry and more persistent cough several times an hour
* tiredness and a need to stay in bed
* feeling breathless when doing moderate exercise (such as walking upstairs)
* muscle pain and aches and need to stay in bed
* headache particularly if you are feeling hot
* sore throat, soreness from coughing, but no pain
* diarrhea
* a dry mouth
6. Adequate venous access
7. For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment. The FDA-approved and cleared methods for birth control are listed below:
* Permanent Sterilization
* Long-Acting Reversible Contraceptives (LARC)
* Contraceptive Injection
* Short-Acting Hormonal Methods
* Barrier Methods
* Emergency Contraception
https://www.fda.gov/consumers/free-publications-women/birth-control
8. Any male subject must agree to use contraceptives and not donate sperm during the study.
9. Must agree to comply with all protocol requirements and be willing to complete all study visits
Exclusion Criteria
1. Patients who have moderate to severe respiratory distress syndrome due to COVID-19
2. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion.
3. Inability to perform any of the assessments required.
4. Active listing (or expected future listing) for transplant of any organ.
5. Be a solid organ transplant recipient. This does not include prior cell-based therapy (\>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
6. History of drug abuse (illegal "street" drugs except marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months
7. Patients with untreated HIV infection. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.
2. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion.
3. Inability to perform any of the assessments required.
4. Active listing (or expected future listing) for transplant of any organ.
5. Be a solid organ transplant recipient. This does not include prior cell-based therapy (\>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
6. History of drug abuse (illegal "street" drugs except marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months
7. Patients with untreated HIV infection. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ZEO ScientifiX, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
Reference Type
BACKGROUND
Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med. 2020 Jan;9(1):28-38. doi: 10.1002/sctm.19-0205. Epub 2019 Oct 24.
Reference Type
BACKGROUND
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. doi: 10.1038/nrd.2015.37. Epub 2016 Feb 12.
Reference Type
BACKGROUND
Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: the "knowns" and "unknowns". J Formos Med Assoc. 2013 Jul;112(7):372-81. doi: 10.1016/j.jfma.2013.05.010. Epub 2013 Jul 21.
Reference Type
BACKGROUND
Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020 Aug;296(2):E32-E40. doi: 10.1148/radiol.2020200642. Epub 2020 Feb 26.
Reference Type
BACKGROUND
Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020 Jun;295(3):715-721. doi: 10.1148/radiol.2020200370. Epub 2020 Feb 13.
Reference Type
BACKGROUND
Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, Hu Q, Xia L. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020 Jun;30(6):3306-3309. doi: 10.1007/s00330-020-06731-x. Epub 2020 Feb 13.
Reference Type
BACKGROUND
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Feb 24.
Reference Type
BACKGROUND
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023 Aug 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK554776/
Reference Type
BACKGROUND
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Reference Type
BACKGROUND
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
Reference Type
BACKGROUND
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
Reference Type
BACKGROUND
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.
Reference Type
BACKGROUND
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
Reference Type
BACKGROUND
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
Reference Type
BACKGROUND
Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Vopr Virusol. 2008 Jul-Aug;53(4):9-13. Russian.
Reference Type
BACKGROUND
Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, Liu JP. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs. Chin J Integr Med. 2020 Apr;26(4):243-250. doi: 10.1007/s11655-020-3192-6. Epub 2020 Feb 17.
Reference Type
BACKGROUND
Center AM. Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19). 2020
Reference Type
BACKGROUND
Hospital B. Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection. 2020.
Reference Type
BACKGROUND
Hospital BY, Shenyang Tonglian Group Co. L, Medicine Io, Biotechnology CAoMS, Hospital HC, University SP, University FAHoCM, University TSAHoHM, City NPsHoF, College FAHBM, University RHoW, Shenyang Tspsho and Hospital NC. The Clinical Study of Carrimycin on Treatment Patients With COVID-19. 2020
Reference Type
BACKGROUND
Hospital T. A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. 2020
Reference Type
BACKGROUND
Hospital T. A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia. 2020
Reference Type
BACKGROUND
Institut National de la Santé Et de la Recherche Médicale F. Trial of Treatments for COVID-19 in Hospitalized Adults. 2020
Reference Type
BACKGROUND
Kong TUoH and Hospital Authority HK. Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment. 2020
Reference Type
BACKGROUND
Ltd. JQPC. Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe). 2020
Reference Type
BACKGROUND
Ltd. JQPC. Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia. 2020
Reference Type
BACKGROUND
Nanchang TNHo and Ascletis Pharmaceuticals Co. L. Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of Novel Coronavirus Infection. 2020
Reference Type
BACKGROUND
University FAHoZ and Ascletis Pharmaceuticals Co. L. Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection. 2020
Reference Type
BACKGROUND
QU J and Hospital R. Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus. 2020
Reference Type
BACKGROUND
University SAHoWM and WanBangDe Pharmaceutical Group Co. L. Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19). 2020
Reference Type
BACKGROUND
Hospital PUF. Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019. 2020
Reference Type
BACKGROUND
Marche UPd and Nord AOORM. Tocilizumab for SARS-CoV2 Severe Pneumonitis. 2020.
Reference Type
BACKGROUND
Chiodini P, Arenare L, Piccirillo MC, Perrone F, Gallo C. A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan. Contemp Clin Trials Commun. 2020 Dec;20:100665. doi: 10.1016/j.conctc.2020.100665. Epub 2020 Oct 7.
Reference Type
BACKGROUND
Hospital T. A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia. 2020
Reference Type
BACKGROUND
Hospital T. Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients. 2020.
Reference Type
BACKGROUND
Peng Z, Ltd TBTC and Hospital Z. Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia. 2020
Reference Type
BACKGROUND
Allergy NIo and Diseases I. Adaptive COVID-19 Treatment Trial. 2020
Reference Type
BACKGROUND
Sciences G. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Severe Coronavirus Disease (COVID-19). 2020
Reference Type
BACKGROUND
Sciences G. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment. 2020.
Reference Type
BACKGROUND
University CM. Severe 2019-nCoV Remdesivir RCT. 2020
Reference Type
BACKGROUND
University CM and Sciences CAoM. Mild/Moderate 2019-nCoV Remdesivir RCT. 2020
Reference Type
BACKGROUND
Center SPHC. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ). 2020
Reference Type
BACKGROUND
Minnesota Uo. Post-exposure Prophylaxis for SARS-Coronavirus-2. 2020.
Reference Type
BACKGROUND
National Institute of Respiratory Diseases M and Sanofi. Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial). 2020.
Reference Type
BACKGROUND
Hospital HPPs. Tetrandrine Tablets Used in the Treatment of COVID-19. 2020
Reference Type
BACKGROUND
Sciences CAoCM. Yinhu Qingwen Decoction for the Treatment of Mild Common CoVID-19. 2020.
Reference Type
BACKGROUND
Wang Z, Hospital WL, University TFAHoDM, Hospital TPs, Science NCUo, Hospital TA, Hospital JEFG and Sciences CAoCM. Yinhu Qingwen Granula for the Treatment of Severe CoVID-19. 2020.
Reference Type
BACKGROUND
Hospital MG, Hospital X and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19. 2020
Reference Type
BACKGROUND
Hospital MG, Hospital X, Fondazione IRCCS Ca' Granda OMP and Hospital N. Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19. 2020
Reference Type
BACKGROUND
Hospital X and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection. 2020.
Reference Type
BACKGROUND
Hospital X, Hospital MG and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. 2020
Reference Type
BACKGROUND
NeuroRx I and SA RTH. Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress. 2020
Reference Type
BACKGROUND
OncoImmune I. CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment. 2020.
Reference Type
BACKGROUND
Wuhan Union Hospital C. Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients. 2020
Reference Type
BACKGROUND
Hospital T. The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19. 2020
Reference Type
BACKGROUND
Hospital PUMC, Tongji Hospital of Tongji Medical College HUoS and Technology. The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia. 2020.
Reference Type
BACKGROUND
Science PHAtWUo, Technology and Wuhan Hamilton Bio-technology Co. L. Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus. 2020
Reference Type
BACKGROUND
Hospital T-D. Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia. 2020
Reference Type
BACKGROUND
Southeast University C. Immunoregulatory Therapy for 2019-nCoV. 2020.
Reference Type
BACKGROUND
Pulmotect I. The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2. 2020
Reference Type
BACKGROUND
Pulmotect I. The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID- 19 in Adults Positive for SARS-CoV-2 Infection. 2020
Reference Type
BACKGROUND
Pharmaceuticals R and Sanofi. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. 2020
Reference Type
BACKGROUND
Peng Z and Hospital Z. Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia. 2020.
Reference Type
BACKGROUND
University FAHoWM, University SAHoWM and Hospital WC. The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia. 2020
Reference Type
BACKGROUND
University FAHoWM, University SAHoWM and Hospital WC. The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19. 2020
Reference Type
BACKGROUND
University FAHoFM. Fingolimod in COVID-19. 2020
Reference Type
BACKGROUND
Hospital BCY. Efficacy and Safety of Corticosteroids in COVID-19. 2020
Reference Type
BACKGROUND
Hospital PUMC, Hospital Z, Hospital Z and University RHoW. Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure. 2020.
Reference Type
BACKGROUND
Hospital T. The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia. 2020.
Reference Type
BACKGROUND
Hospital B, CELL V, GENE ENGINEERING CORP. L, China, Wuhan Huoshenshan Hospital W, China, Hospital TH, Hospital STPs, Fifth Affiliated Hospital SY-SU, Wuhan Union Hospital C and Hospital WC. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19). 2020
Reference Type
BACKGROUND
Hospital B, Innovative Precision Medicine Group H, China., Wuhan Huoshenshan Hospital W, China, Hospital TH, CELL V, GENE ENGINEERING CORP. L, China, Hospital STPs and Fifth Affiliated Hospital SY-SU. Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus. 2020.
Reference Type
BACKGROUND
CAR-T Biotechnology Co. L. Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells. 2020.
Reference Type
BACKGROUND
Wuhan Union Hospital C and Wuhan Hamilton Bio-technology Co. L, China. Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia. 2020.
Reference Type
BACKGROUND
Arabia SC. Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells. 2020.
Reference Type
BACKGROUND
Brasil A, Ltda CPC and Cruz HV. Mesenchymal Stem Cell NestCell® to Treat Patients With Severe COVID-19 Pneumonia. 2020
Reference Type
BACKGROUND
Inc. TSCB. Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2. 2020
Reference Type
BACKGROUND
University Xm and University FAHoXM. NK Cells Treatment for Novel Coronavirus Pneumonia. 2020
Reference Type
BACKGROUND
Tasly Pharmaceuticals I. The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19. 2020
Reference Type
BACKGROUND
Hospital T. A Pilot Study of Sildenafil in COVID-19. 2020.
Reference Type
BACKGROUND
Minnesota Uo. Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization. 2020.
Reference Type
BACKGROUND
Minnesota Uo. Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization. 2020.
Reference Type
BACKGROUND
Hospital S, Medicine HHoTC, Hospital JNPs and Hospital T. Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu. 2020
Reference Type
BACKGROUND
Munoz-Fernandez R, Prados A, Leno-Duran E, Blazquez A, Garcia-Fernandez JR, Ortiz-Ferron G, Olivares EG. Human decidual stromal cells secrete C-X-C motif chemokine 13, express B cell-activating factor and rescue B lymphocytes from apoptosis: distinctive characteristics of follicular dendritic cells. Hum Reprod. 2012 Sep;27(9):2775-84. doi: 10.1093/humrep/des198. Epub 2012 Jun 20.
Reference Type
BACKGROUND
Castro-Manrreza ME, Mayani H, Monroy-Garcia A, Flores-Figueroa E, Chavez-Rueda K, Legorreta-Haquet V, Santiago-Osorio E, Montesinos JJ. Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev. 2014 Jun 1;23(11):1217-32. doi: 10.1089/scd.2013.0363. Epub 2014 Feb 24.
Reference Type
BACKGROUND
Fontaine MJ, Shih H, Schafer R, Pittenger MF. Unraveling the Mesenchymal Stromal Cells' Paracrine Immunomodulatory Effects. Transfus Med Rev. 2016 Jan;30(1):37-43. doi: 10.1016/j.tmrv.2015.11.004. Epub 2015 Dec 1.
Reference Type
BACKGROUND
Najar M, Krayem M, Merimi M, Burny A, Meuleman N, Bron D, Raicevic G, Lagneaux L. Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts. Inflamm Res. 2018 Jun;67(6):467-477. doi: 10.1007/s00011-018-1131-1. Epub 2018 Jan 23.
Reference Type
BACKGROUND
Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, Wang Y. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018 Aug;14(8):493-507. doi: 10.1038/s41581-018-0023-5.
Reference Type
BACKGROUND
Bagno L, Hatzistergos KE, Balkan W, Hare JM. Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges. Mol Ther. 2018 Jul 5;26(7):1610-1623. doi: 10.1016/j.ymthe.2018.05.009. Epub 2018 May 25.
Reference Type
BACKGROUND
Karantalis V, Schulman IH, Balkan W, Hare JM. Allogeneic cell therapy: a new paradigm in therapeutics. Circ Res. 2015 Jan 2;116(1):12-5. doi: 10.1161/CIRCRESAHA.114.305495. No abstract available.
Reference Type
BACKGROUND
Casiraghi F, Remuzzi G, Abbate M, Perico N. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev Rep. 2013 Feb;9(1):65-79. doi: 10.1007/s12015-011-9345-4.
Reference Type
BACKGROUND
Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012 Jan;20(1):14-20. doi: 10.1038/mt.2011.211. Epub 2011 Oct 18.
Reference Type
BACKGROUND
Li X, Yue S, Luo Z. Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget. 2017 May 23;8(60):102600-102616. doi: 10.18632/oncotarget.18126. eCollection 2017 Nov 24.
Reference Type
BACKGROUND
Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009 Mar 15;433(1-2):1-7. doi: 10.1016/j.gene.2008.12.008. Epub 2008 Dec 24.
Reference Type
BACKGROUND
Cajal FplIBdHURy, III IdSC and pulmonar FdAalIslH. Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies. 2019
Reference Type
BACKGROUND
Hospital D, University tRIoSotTMM, University CsHoCM, Maternal C and Hospital CH. Stem Cells for Bronchopulmonary Dysplasia. 2017.
Reference Type
BACKGROUND
Ltd. MC. PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants. 2018
Reference Type
BACKGROUND
University CsHoCM. Follow-Up Study of Mesenchymal Stem Cells for Bronchopulmonary Dysplasia. 2018.
Reference Type
BACKGROUND
University CsHoCM. Human Mesenchymal Stem Cells For Infants At High Risk For Bronchopulmonary Dysplasia. 2019
Reference Type
BACKGROUND
Center MDAC and Foundation K. Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies. 2017
Reference Type
BACKGROUND
Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, O'Kane C, McAuley DF. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Trials. 2020 Jun 3;21(1):462. doi: 10.1186/s13063-020-04416-w.
Reference Type
BACKGROUND
University SY-s. Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS. 2018.
Reference Type
BACKGROUND
Clinic M. Mesenchymal Stem Cell Therapy for Lung Rejection. 2014
Reference Type
BACKGROUND
Clinic M. Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD). 2020.
Reference Type
BACKGROUND
Mesoblast I and Mesoblast L. PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). 2008.
Reference Type
BACKGROUND
Clinica Universidad de Navarra UdN. Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis. 2013
Reference Type
BACKGROUND
Dai J, Southwest Hospital C and Sciences CAo. A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells. 2014.
Reference Type
BACKGROUND
Hare JM, Lester T, Foundation SS, The Emmes Company L and Miami Uo. Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER). 2013.
Reference Type
BACKGROUND
Hospital TPC and Institute MMR. A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis. 2010.
Reference Type
BACKGROUND
Dai J, Southwest Hospital C, Hospital NC and Sciences CAo. A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells. 2016.
Reference Type
BACKGROUND
Glassberg M and Miami Uo. Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis. 2016.
Reference Type
BACKGROUND
Glassberg M and Miami Uo. Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma. 2017
Reference Type
BACKGROUND
Hare JM and Miami Uo. Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis. 2020.
Reference Type
BACKGROUND
Roesch EA, Bonfield TL, Lazarus HM, Reese J, Hilliard K, Hilliard J, Khan U, Heltshe S, Gluvna A, Dasenbrook E, Caplan AI, Chmiel JF. A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis. J Cyst Fibros. 2023 May;22(3):407-413. doi: 10.1016/j.jcf.2022.12.001. Epub 2022 Dec 20.
Reference Type
BACKGROUND
Hospital LPs. Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension. 2019
Reference Type
BACKGROUND
Da Sacco S, De Filippo RE, Perin L. Amniotic fluid as a source of pluripotent and multipotent stem cells for organ regeneration. Curr Opin Organ Transplant. 2011 Feb;16(1):101-5. doi: 10.1097/MOT.0b013e3283424f6e.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19881-EA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Convalescent Plasma for the Treatment of COVID-19
NCT04389710
COMPLETED
PHASE2
Sotrovimab Expanded Access Treatment Protocol (COVID-19)
NCT05235347
NO_LONGER_AVAILABLE
Study of Sargramostim in Patients With COVID-19
NCT04411680
COMPLETED
PHASE2
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
NCT04360486
NO_LONGER_AVAILABLE
Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
NCT05074394
WITHDRAWN
PHASE2
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)
NCT04657497
COMPLETED
PHASE3
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
NCT05077332
COMPLETED
PHASE2
The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin
NCT04601077
TERMINATED
PHASE1/PHASE2
Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients
NCT04449380
TERMINATED
PHASE2
Efficacy of Tocilizumab on Patients With COVID-19
NCT04356937
COMPLETED
PHASE3
Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts
NCT05415241
UNKNOWN
PHASE1/PHASE2
Convalescent Plasma Therapy - Zurich Protocol
NCT04869072
COMPLETED
PHASE1
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
NCT04438057
COMPLETED
PHASE2
Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals
NCT04681430
COMPLETED
PHASE2
SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation
NCT04631705
TERMINATED
PHASE1/PHASE2
Defibrotide for the Treatment of Severe COVID-19
NCT04652115
RECRUITING
PHASE2
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)
NCT04397692
TERMINATED
NA
Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study
NCT04606498
UNKNOWN
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19
NCT04467151
WITHDRAWN
PHASE2
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
NCT04661839
COMPLETED
PHASE1
A Study of N-acetylcysteine in Patients With COVID-19 Infection
NCT04374461
ACTIVE_NOT_RECRUITING
PHASE2
LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19
NCT05783180
WITHDRAWN
PHASE2
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
NCT05372783
WITHDRAWN
PHASE2
A Phase III Confirmatory Study of K-237
NCT05056883
COMPLETED
PHASE3
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
NCT04364737
COMPLETED
PHASE2